If there is an India or Asia market, UNI will meet its needs.
That won't help RXPC. Their patent expires in five weeks and after that time, UNI can manufacture and market the test in India and Asia without paying Radient a penny. Since Radient has no manufacturing facility anywhere, and in fact doesn't even have an office anywhere, I fail to see how an Asia market would affect Radient in any way.
SRL has no expansion plans. They merely bought some test kits from Guar Diagno when Guar Diagno failed to sell them. SRL sold those kits for half price in 2013 and today SRL is not involved with Radient, DR-70, or onko-sure.
